Agrimonolide inhibits cancer progression and induces ferroptosis and apoptosis by targeting SCD1 in ovarian cancer cells. 2022

Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
Department of Obstetrics and Gynecology, Yantai Zhifu Hospital, Yantai, Shandong, 266000, P.R. China.

BACKGROUND Ovarian cancer is a gynaecological tumour has high incidence and mortality rates. Agrimonolide, isolated from Agrimonia pilosa Ledeb, has multiple biomedical activities, including anticancer activity. OBJECTIVE Here, we aimed to reveal the function of agrimonolide on ovarian cancer progression. METHODS MTT assay, colony-formation assay, flow cytometry, transwell assay, scratch test, western immunoblotting, reactive oxygen species (ROS) detection, and ferroptosis analysis were performed to reveal the role and underlying mechanisms of agrimonolide in ovarian cancer cell lines (A2780 and SKOV-3). The effects of agrimonolide on the SKOV-3 xenograft model were also studied. RESULTS Agrimonolide dose-dependently inhibited proliferation, migration, and invasion and promoted apoptosis in A2780 and SKOV-3 cells. Agrimonolide induced ferroptosis in tumour cells, evidenced by the increased levels of ROS, total iron, and Fe2+ and downregulation of ferroptosis indicators (SLC7A11 and GPX4). The SwissTargetPrediction and Comparative Toxicogenomics Database predicted SCD1 as a target protein for agrimonolide. Molecular Operating Environment software docked agrimonolide in the SCD1 protein, and the binding energy of interaction was -8.21 kcal/mol. The effects of agrimonolide on proliferation, invasion, and induction of apoptosis and ferroptosis were attenuated by SCD1 overexpression in A2780 and SKOV-3 cells. Additionally, agrimonolide attenuated the tumour growth of ovarian cancer in the SKOV-3 xenograft model and significantly downregulated SCD1 in tumour tissues. CONCLUSIONS Our study is the first to suggest that agrimonolide acts as a novel apoptosis- and ferroptosis-inducing agent in ovarian cancer cells by targeting SCD1. Agrimonolide may be a novel therapeutic agent for treating ovarian cancer.

UI MeSH Term Description Entries
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000079403 Ferroptosis A form of REGULATED CELL DEATH initiated by oxidative perturbations of the intracellular microenvironment that is under constitutive control by glutathione peroxidase 4 and can be inhibited by iron chelators and lipophilic antioxidants. Oxytosis
D013230 Stearoyl-CoA Desaturase An enzyme that catalyzes the formation of oleoyl-CoA, A, and water from stearoyl-CoA, AH2, and oxygen where AH2 is an unspecified hydrogen donor. Stearyl-CoA Desaturase,Stearate Desaturase,delta-9 Desaturase,Desaturase, Stearate,Desaturase, Stearoyl-CoA,Desaturase, Stearyl-CoA,Desaturase, delta-9,Stearoyl CoA Desaturase,Stearyl CoA Desaturase,delta 9 Desaturase
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D017382 Reactive Oxygen Species Molecules or ions formed by the incomplete one-electron reduction of oxygen. These reactive oxygen intermediates include SINGLET OXYGEN; SUPEROXIDES; PEROXIDES; HYDROXYL RADICAL; and HYPOCHLOROUS ACID. They contribute to the microbicidal activity of PHAGOCYTES, regulation of SIGNAL TRANSDUCTION and GENE EXPRESSION, and the oxidative damage to NUCLEIC ACIDS; PROTEINS; and LIPIDS. Active Oxygen Species,Oxygen Radical,Oxygen Radicals,Pro-Oxidant,Reactive Oxygen Intermediates,Active Oxygen,Oxygen Species, Reactive,Pro-Oxidants,Oxygen, Active,Pro Oxidant,Pro Oxidants,Radical, Oxygen
D045744 Cell Line, Tumor A cell line derived from cultured tumor cells. Tumor Cell Line,Cell Lines, Tumor,Line, Tumor Cell,Lines, Tumor Cell,Tumor Cell Lines
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D049934 Isocoumarins Compounds that differ from COUMARINS in having the positions of the ring and ketone oxygens reversed so the keto oxygen is at the 1-position of the molecule. Isocoumarin,1-Isochromen-1-ones,1H-2-Benzopyran-1-ones

Related Publications

Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
March 2024, Journal of agricultural and food chemistry,
Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
April 2024, Photodiagnosis and photodynamic therapy,
Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
March 2024, Cellular and molecular biology (Noisy-le-Grand, France),
Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
December 2017, Oncology letters,
Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
March 2022, Journal of ovarian research,
Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
November 2022, Annals of translational medicine,
Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
January 2017, American journal of cancer research,
Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
January 2023, American journal of cancer research,
Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
August 2022, Oncology letters,
Ying Liu, and Xiaobei Liu, and Hui Wang, and Pingping Ding, and Changlin Wang
January 2015, International journal of clinical and experimental pathology,
Copied contents to your clipboard!